GENEVA: Thousands of experimental Ebola vaccine doses from British GSK and US NewLink should be ready for use by early 2015 in countries affected by the epidemic, WHO’s assistant director general Marie-Paule Kieny said that they are giving their best possible efforts to use few of these vaccines in some of the affected countries at the very beginning of 2015. There is no licensed treatment or vaccine against the virus that has killed nearly 3,000 people in Africa, and the UN health agency has endorsed rushing through experimental treatments and vaccines.
Kieny also said that:
World Health Organisation is especially concentrating on 2 experimental vaccines, one made by British company GSK (GlaxoSmithKline), and the other by US group NLG (NewLink Genetics) and she is coordinating with both the companies to accelerate clinical proceedings & trials. Some clinical trials have begun in the United State, and others are set to begin in Mali next week.
According to the agency if they found that it is safe, then some doses should be available for use to healthcare workers by the end of this year around November and wider use could be possible early in starting of next year. The Canadian government has already donated 800 viles of the NLG vaccine to World Health Organisation, and She said thousands of doses would likely be available in coming few months.
Around 10,000 doses of the GSK vaccine should also be available by then “This is not a vaccine, this is a candidate vaccine,” pointing to the need for showing great caution in rolling out the vaccines more broadly. The two candidate vaccines “have given very promising results on animals, but they are animals not humans,” she said.
Another experimental vaccine by US company J&J (Johnson & Johnson) had not been ruled out, but “they are clearly behind by just few months,”.